Selective increase in plasma tumor necrosis factor-α and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis

Journal of Infectious Diseases

Volumn 178, Issue 2, 1998, Pages 580-584

  Bekker, L G ^b   Maartens, G ^b   Steyn, L ^b   Kaplan, G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; ETHAMBUTOL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; ISONIAZID; LACTIC ACID; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0031850586     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517479     Document Type: Article

References (15)

1. Newcombe JF. Tuberculous cervical lymphadenopathy. Postgrad Med J 1971;47:713-4.
2. Lees AJ, MacLeod AF, Marshall J. Cerebral tuberculomas developing during treatment of tuberculous meningitis. Lancet 1980; 1:1208-11.
3. Onwubalili JK, Scott GM, Smith H. Acute respiratory distress related to chemotherapy of advanced pulmonary tuberculosis: a study of two cases and review of the literature. Q J Med 1986;230:599-610.
4. Moreno C, Taverne J, Mehlert A, et al. Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin Exp Immunol 1989; 76: 240-5.
5. Aung H, Toossi Z, Wisnieski JJ, et al. Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin. J Clin Invest 1996; 98:1261-8.
6. Youmans GP. Mechanisms of immunity in tuberculosis. Pathobiol Annu 1979;9:137-62.
7. Koch R. Weitere Mittheilungen über ein Heilmittel gegen Tuberculose. Dtsch Med Wochenschr 1890; 16:1029.
8. Kamofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of chemotherapeutic agents. Proceedings of Symposium at the New York Academy of Medicine. New York: Columbia University Press, 1949:191-205.
9. Kindler V, Sappino AP, Grau GE, Pignet PF, Vassalli P. The inducing role of tumour necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-40.
10. Bermudez LEM, Young LS. Tumour necrosis factor alone or in combination with IL-2, but not IFN-γ, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988; 140: 3006-13.
11. Beutler B, Cerami A. Cachectin: more than a tumour necrosis factor. N Engl J Med 1987;316:379-85.
12. Bucklin SE, Morrison DC. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. J Infect Dis 1995; 172:1519-27.
13. Johnson BJ, Ress SR, Willcox P, et at. Clinical and immune responses of tuberculosis patients treated with low dose IL-2 and multi-drug therapy. Cytokines Mol Ther 1995; 1:185-96.
14. Mangge H, Kenzian H, Gallistl S, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995;38: 211-20.
15. Thea DM, Porat R, Nagimbi K, et al. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1. Ann Intern Med 1996; 124:757-62.